Targeting alpha-synuclein for the treatment of Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 2, 2012, Pages 174-179

  Rohn, Troy T ^a  

^a BOISE STATE UNIVERSITY   (United States)

Author keywords

Alpha synuclein; Immunization; Immunotherapy; Lewy bodies; Parkinson's disease; Toxins; Virus

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CALPAIN 1;

ARTICLE; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; LEWY BODY; NITRATION; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN UNFOLDING;

EID: 84860484992     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800269678     Document Type: Article

References (65)

1. Gibb, W.R. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol. Appl. Neurobiol., 1986, 12, 223-234.
2. de Lau, L.M.; Breteler, M.M. Epidemiology of Parkinson's disease. Lancet Neurol., 2006, 5, 525-535.
3. Wirdefeldt, K.; Adami, H.O.; Cole, P.; Trichopoulos, D.; Mandel, J.; Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol., 2011, 26(Suppl 1), S1-S58.
4. Lees, A. The bare essentials: Parkinson's disease. Pract. Neurol., 2010, 10, 240-246.
5. Shulman, J.M.; De Jager, P.L.; Feany, M.B. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol., 2011, 6, 193-222.
6. Ravenholt, R.T.; Foege, W.H. 1918 influenza, encephalitis lethargica, parkinsonism. Lancet, 1982, 2, 860-864.
7. Kumar, A.; Calne, S.M.; Schulzer, M.; Mak, E.; Wszolek, Z.; Van Netten, C.; Tsui, J.K.; Stoessl, A.J.; Calne, D.B. Clustering of Parkinson disease: shared cause or coincidence? Arch. Neurol., 2004, 61, 1057-1060.
8. Goldsmith, J.R.; Herishanu, Y.O.; Podgaietski, M.; Kordysh, E. Dynamics of parkinsonism-Parkinson's disease in residents of adjacent kibbutzim in Israel's Negev. Environ. Res., 1997, 73, 156-161.
9. Rohn, T.T.; Catlin, L.W. Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain. PLoS One, 2011, 6, e20495.
10. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219, 979-980.
11. Priyadarshi, A.; Khuder, S.A.; Schaub, E.A.; Shrivastava, S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology, 2000, 21, 435-440.
12. Cicchetti, F.; Lapointe, N.; Roberge-Tremblay, A.; Saint-Pierre, M.; Jimenez, L.; Ficke, B.W.; Gross, R.E. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol. Dis., 2005, 20, 360-371.
13. Manning-Bog, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes up- regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 2002, 277, 1641-1644.
14. Thiruchelvam, M.; Brockel, B.J.; Richfield, E.K.; Baggs, R.B.; Cory-Slechta, D.A.; Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res., 2000, 873, 225-234.
15. Thiruchelvam, M.; Richfield, E.K.; Baggs, R.B.; Tank, A.W.; Cory-Slechta, D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci., 2000, 20, 9207-9214.
16. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 2000, 3, 1301-1306.
17. Coulom, H.; Birman, S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J. Neurosci., 2004, 24, 10993-10998.
18. Sherer, T.B.; Kim, J.H.; Betarbet, R.; Greenamyre, J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol., 2003, 179, 9-16.
19. Mandel, J.S.; Adami, H.O.; Cole, P. Paraquat and Parkinson's disease: An overview of the epidemiology and a review of two recent studies. Regul. Toxicol. Pharmacol., 2012, 62(2), 385-392.
20. Lewy, F.H. Paralysis Agitans. Pathologische A., Ed.; Springer-Verlag, Berlin 1912.
21. Tofaris, G.K.; Spillantini, M.G. Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord., 2005, 20(Suppl 12), S37-S44.
22. Olanow, C.W.; Perl, D.P.; DeMartino, G.N.; McNaught, K.S. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol., 2004, 3, 496-503.
23. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
24. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA, 1998, 95, 6469-6473.
25. Dickson, D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol., 2001, 14, 423-432.
26. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T., Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35, 13709-13715.
27. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 2002, 4, 160-164.
28. Duda, J.E.; Giasson, B.I.; Chen, Q.; Gur, T.L.; Hurtig, H.I.; Stern, M.B.; Gollomp, S.M.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol., 2000, 157, 1439-1445.
29. Mishizen-Eberz, A.J.; Guttmann, R.P.; Giasson, B.I.; Day, G.A., 3rd; Hodara, R.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q.; Lynch, D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem., 2003, 86, 836-847.
30. Lundvig, D.; Lindersson, E.; Jensen, P.H. Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res., 2005, 134, 3-17.
31. Li, W.; West, N.; Colla, E.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, T.M.; Jakala, P.; Hartmann, T.; Price, D.L.; Lee, M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA, 2005, 102, 2162-2167.
32. Liu, C.W.; Giasson, B.I.; Lewis, K.A.; Lee, V.M.; Demartino, G.N.; Thomas, P.J. A precipitating role for truncated alpha- synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem., 2005, 280, 22670-22678.
33. Bennett, M.C.; Bishop, J.F.; Leng, Y.; Chock, P.B.; Chase, T.N.; Mouradian, M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem., 1999, 274, 33855-33858.
34. Ancolio, K.; Alves da Costa, C.; Ueda, K.; Checler, F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr- alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett., 2000, 285, 79-82.
35. Paxinou, E.; Chen, Q.; Weisse, M.; Giasson, B.I.; Norris, E.H.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M.; Ischiropoulos, H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci., 2001, 21, 8053-8061.
36. Vanderklish, P.W.; Bahr, B.A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol., 2000, 81, 323-339.
37. Glading, A.; Lauffenburger, D.A.; Wells, A. Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol., 2002, 12, 46-54.
38. Dufty, B.M.; Warner, L.R.; Hou, S.T.; Jiang, S.X.; Gomez-Isla, T.; Leenhouts, K.M.; Oxford, J.T.; Feany, M.B.; Masliah, E.; Rohn, T.T. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol., 2007, 170, 1725-1738.
39. Schapira, A.H. Complex I: inhibitors, inhibition and neurodegeneration. Exp. Neurol., 2010, 224, 331-335.
40. Przedborski, S.; Tieu, K.; Perier, C.; Vila, M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr., 2004, 36, 375-379.
41. Song, D.D.; Shults, C.W.; Sisk, A.; Rockenstein, E.; Masliah, E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol., 2004, 186, 158-172.
42. Belal, C.; Ameli, N.J.; El Kommos, A.; Bezalel, S.; Al'khafaji, A.M.; Mughal, M.R.; Mattson, M.P.; Kyriazis, G.A.; Tyrberg, B.; Chan, S.L. The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant alpha-synuclein- induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins. Hum. Mol. Genet., 2012, 21(5), 963-977.
43. Surmeier, D.J.; Guzman, J.N.; Sanchez-Padilla, J.; Goldberg, J.A. What causes the death of dopaminergic neurons in Parkinson's disease? Prog. Brain Res., 2010, 183, 59-77.
44. Windisch, M.; Wolf, H.J.; Hutter-Paier, B.; Hofmeister, A.; Wronski, R. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr. Alzheimer Res., 2007, 4, 446-457.
45. Danzer, K.M.; McLean, P.J. Drug targets from genetics: alpha-synuclein. CNS Neurol. Disord. Drug Targets, 2011, 10, 712-723.
46. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302, 819-822.
47. Winslow, A.R.; Rubinsztein, D.C. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy, 2011, 7, 429-431.
48. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 2001, 276, 10737-10744.
49. Outeiro, T.F.; Putcha, P.; Tetzlaff, J.E.; Spoelgen, R.; Koker, M.; Carvalho, F.; Hyman, B.T.; McLean, P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One, 2008, 3, e1867.
50. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci., 2007, 27, 9220-9232.
51. Tsika, E.; Moysidou, M.; Guo, J.; Cushman, M.; Gannon, P.; Sandaltzopoulos, R.; Giasson, B.I.; Krainc, D.; Ischiropoulos, H.; Mazzulli, J.R. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J. Neurosci., 2010, 30, 3409-3418.
52. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature, 1999, 400, 173-177.
53. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.
54. Menendez-Gonzalez, M.; Perez-Pinera, P.; Martinez-Rivera, M.; Muniz, A.L.; Vega, J.A. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr. Pharm. Des., 2011, 17, 508-520.
55. Saxena, U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Expert Opin. Ther. Targets, 2010, 14, 1273-1277.
56. Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; Games, D.; Schenk, D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron, 2005, 46, 857-868.
57. Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T.T.; Mueller- Steiner, S.; Seubert, P.; Barbour, R.; McConlogue, L.; Buttini, M.; Games, D.; Schenk, D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 2011, 6, e19338.
58. Delrieu, J.; Ousset, P.J.; Caillaud, C.; Vellas, B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J. Neurochem., 2012, 120(Suppl 1), 186-193.
59. Nasstrom, T.; Goncalves, S.; Sahlin, C.; Nordstrom, E.; Screpanti Sundquist, V.; Lannfelt, L.; Bergstrom, J.; Outeiro, T.F.; Ingelsson, M. Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One, 2011, 6, e27230.
60. Angot, E.; Steiner, J.A.; Hansen, C.; Li, J.Y.; Brundin, P. Are synucleinopathies prion-like disorders? Lancet Neurol., 2010, 9, 1128-1138.
61. El-Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Cooper, L.J.; Fullwood, N.J.; Gibson, M.J.; Curran, M.D.; Court, J.A.; Mann, D.M.; Ikeda, S.; Cookson, M.R.; Hardy, J.; Allsop, D. Alpha- synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J., 2003, 17, 1945-1947.
62. Desplats, P.; Lee, H.J.; Bae, E.J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; Lee, S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA, 2009, 106, 13010-13015.
63. Lee, H.J.; Suk, J.E.; Patrick, C.; Bae, E.J.; Cho, J.H.; Rho, S.; Hwang, D.; Masliah, E.; Lee, S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem., 2010, 285, 9262-9272.
64. Lim, Y.; Kehm, V.M.; Lee, E.B.; Soper, J.H.; Li, C.; Trojanowski, J.Q.; Lee, V.M. Alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci., 2011, 31, 10076-10087.
65. Mickiewicz, A.L.; Kordower, J.H. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol. Disord. Drug Targets, 2011, 10, 703-711.